newsroom.csl

CSL and uniQure Win 2023 Prix Galien USA Award

HEMGENIX ®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass., Oct. 27, 2023 ...
Global Newsroom | CSL

CSL Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic ...

CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the ...
Global Newsroom | CSL

Australian scientists awarded $2.5 million CSL Centenary Fellowships to advance lifelong immunity research and AI-designed proteins

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The ...
newsroom.csl

Global Newsroom

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University... CSL ...
newsroom.csl

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...
Global Newsroom | CSL

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, ...